GSK seized the opportunity to buy Sierra three months after it reported positive topline data for its lead candidate momelotinib from the Phase III MOMENTUM trial. Sierra is expected to file a New Drug Application for momelotinib this year. GSK’s deal caps a 14-year period that saw momelotinib change hands from original developer Cytopia to YM Biosciences in 2009, to Gilead Sciences three years later, then to Sierra in 2018 . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge